Dilon Technologies develops surgical and diagnostic medical devices, including HEMOBLAST Bellows, MarginProbe, and the Navigator Gamma Probe. HEMOBLAST Bellows is used in several hundred U.S. hospitals and is the only FDA‑approved product specifically indicated for control of minimal, mild, and moderate bleeding. MarginProbe is an intraoperative breast margin assessment device shown in studies to reduce re‑excision rates by 25%–80%; a next‑generation MarginProbe has been submitted to the FDA with approval anticipated by year‑end. The Navigator Gamma Probe product line remains a market leader for radio‑guided lymphatic mapping and tumor localization, with an enhanced version expected by late 2025. The company reported continued double‑digit growth and intends to use new capital to scale operations and support its product pipeline.

Total raised

$9M

Funding rounds

1

Latest round

Equity

Latest activity

Jun 2025